**Brianna Kimball, PharmD, BCACP, CDOE**

***Published Articles***

* **Kimball, BK**, Tutalo, RA, Minami, T, Eaton, CB. Evaluating an integrated chronic obstructive pulmonary disease management program implemented in a primary care setting. *J Am Coll Clin Pharm*. 2021; 4: 697– 710. [https://doi.org/10.1002/jac5.1428](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1002%2Fjac5.1428&data=05%7C01%7CSRanucci%40ripcpc.com%7C78b088feebdb4ea6acf608db6e83b8c6%7C529ac06642c7499ab6dd3f860727916d%7C0%7C0%7C638225285284158189%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=OC6ba2wQUSIq51SaAl3f6cn7EWb5iqPYv5YjZi%2FQ0fs%3D&reserved=0) Available from: [Evaluating an integrated chronic obstructive pulmonary disease management program implemented in a primary care setting (wiley.com)](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Faccpjournals.onlinelibrary.wiley.com%2Fdoi%2Fepdf%2F10.1002%2Fjac5.1428&data=05%7C01%7CSRanucci%40ripcpc.com%7C78b088feebdb4ea6acf608db6e83b8c6%7C529ac06642c7499ab6dd3f860727916d%7C0%7C0%7C638225285284158189%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=sn9T7uAn0JM4qEEJ2iXAWSuqyoPQbL1at%2BPvWznXlbM%3D&reserved=0).
* **Kimball B,** Hume A. Echinacea. *Pharmacy Today*. 2019; (25): 15. Available from: doi: 10.1016/j.ptdy.2019.11.006.
* Crouch M, **Kimball, B.** Taking Multiple Medications? Beware of Side Effects*.* *AARP.* Published January 31, 2022. Available from: <https://www.aarp.org/health/drugs-supplements/info-2022/medication-overload.html>.

**Jessica Silva, PharmD, CDOE**

***Published Articles***

* **Silva, J.** Bratberg, J, Lemay, V. Covid-19 and influenza vaccine hesitancy among college students. *JAPhA, 2021; Volume 61, Issue 6, P709-714 E1.* Available from: <https://doi.org/10.1016/j.japh.2021.05.009>.
* Awarded certificate of outstanding contribution in April 2022.
* Earned the distinction of being an Outstanding Author for the Journal of the American Pharmacists Association by authoring one of JAPhA’s most downloaded articles in 2021.

**Joseph Nardolillo, PharmD, BCACP**

|  |  |
| --- | --- |
| ***Published Articles*** | |
| * Astle KA\*, Hart LA, Holloway J, Medlin CG, Mills AR**, Nardolillo JA**, Phan T, Wilby KJ. Born This Way: Integrating LGBTQIA+ Identities as Pharmacy Practitioners. *Am J Pharm Educ.* 2023. Epub ahead of print. Available from: <https://doi.org/10.1016/j.ajpe.2023.100122>. |
|  |
| * Litten KP, McQuade BM, Wettergreen SA, **Nardolillo JA**, Stewart MP\*. Failure to fail - Perspective from junior faculty preceptors on the challenges of evaluating underperforming students in the experiential learning environment. *Curr Pharm Teach Learn*. 2023;15(3):238-241. doi:10.1016/j.cptl.2023.03.002 Available from: [Failure to fail – Perspective from junior faculty preceptors on the challenges of evaluating underperforming students in the experiential learning environment - ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S1877129723000448). |
|  |
| * **Nardolillo JA\***, Rosario N, Cheng V, Lobkovich A. Initiating Primary Care Services when the World Is Paused: Lessons for Pharmacists in the Post-COVID-19 Era. *J Pharm Pract*. 2022 Apr 19:8971900221087934. Available from: [Initiating Primary Care Services when the World Is Paused: Lessons for Pharmacists in the Post–COVID-19 Era - Joseph A. Nardolillo, Natalie Rosario, Vivian Cheng, Alison M. Lobkovich, 2022 (sagepub.com)](https://journals.sagepub.com/doi/10.1177/08971900221087934). |
|  |
| * Mohammad I\*, Lobkovich A, **Nardolillo J**, Wilhelm S. Pharmacy Student Satisfaction and Perceptions Following a Virtual Sterile Compounding Experience. *Int J Pharm Compd*. 2022 Jan-Feb;26(1):10-17 Available from: [Pharmacy Student Satisfaction and Perceptions Following a Virtual Sterile Compounding Experience. - Abstract - Europe PMC](https://europepmc.org/article/MED/35081039). |
|  |
| * George J, Lobkovich A, **Nardolillo J**, Farhat N, Kolander S, Thomas E\*. Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration. *Am J Health Syst Pharm*. 2022;79(14):1151-1157. Available from: [Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration | American Journal of Health-System Pharmacy | Oxford Academic (oup.com)](https://academic.oup.com/ajhp/article-abstract/79/14/1151/6524617?redirectedFrom=fulltext). |
|  |
| * Navin SF\*, **Nardolillo J**, Stambaugh A, Young C, Nguyen P, Apodaca M. Pharmacist monitoring of direct oral anticoagulants for American Indians and Alaska Natives in the outpatient setting. *J Am Pharm Assoc*. 2021 Oct 14:S1544-3191(21)00428-3. doi: 10.1016/j.japh.2021.10.009. Available from: [Pharmacist monitoring of direct oral anticoagulants for American Indians and Alaska Natives in the outpatient setting - Journal of the American Pharmacists Association (japha.org)](https://www.japha.org/article/S1544-3191(21)00428-3/fulltext). |
|  |
| * **Nardolillo JA**, Marrs JC\*, Anderson SL, Hanratty R, Saseen JJ. Retrospective cohort study of statin prescribing for primary prevention among people living with HIV. *JRSM Cardiovasc Dis*. 2021 Jul 12;10:2048004021103106. Available from: [Retrospective cohort study of statin prescribing for primary prevention among people living with HIV - Joseph A Nardolillo, Joel C Marrs, Sarah L Anderson, Rebecca Hanratty, Joseph J Saseen, 2021 (sagepub.com)](https://journals.sagepub.com/doi/full/10.1177/20480040211031068). |

|  |  |
| --- | --- |
| ***Multimedia Publications*** | |
| ***Written*** |
| * **Nardolillo JA**, Cheng V**.** Is Icosapent Ethyl a QAL-tY Investment? *iForumRX Peer-Reviewed Commentary.* December 2022. Available from: <https://iforumrx.org/icosapent-ethyl-cost-effectiveness/>. |
|  |
| * **Nardolillo JA.** Review Before You Renew: Implicit Bias Training. *Michigan Society of Health System Pharmacists (MSHP) Monitor*. June 2022. |
|  |
| * **Nardolillo JA.** Review Before You Renew: Updated Continuing Education Requirements for Pharmacists. *Michigan Society of Health System Pharmacists (MSHP) Monitor*. March 2021. |
|  |
| * Wettergreen S, **Nardolillo JA.** Powerful Placebos and Notorious Nocebos: Implications for Ambulatory Care*. iForumRX Peer-Reviewed Commentary*. July 2020. Available from: <https://iforumrx.org/powerful-placebos-and-notorious-nocebos-implications-for-ambulatory-care>. |
| ***Podcasts*** |
| * **Nardolillo JA,** Cheng V**.** Is Icosapent Ethyl a QAL-tY Investment*? iForumRX podcast.* *December 2022.* Available from: <https://iforumrx.org/icosapent-ethyl-cost-effectiveness>. |
|  |
| * **Nardolillo JA**. Providing Inclusive Care for the LGBTQ+ Community. *Pharmacy Quality Solutions Quality Corner podcast. June 2022.* Available from: <https://pharmacyquality.buzzsprout.com/726174/10790340-providing-inclusive-care-for-the-lgbtq-community>. |
|  |
| * Johnson B, **Nardolillo JA**, Link Patterson M, Tenpas A, **Osunsanmi T, Martirosov AL**. Action in Ambulatory Care: Striving for Diversity, Equity, and Inclusion. *American Society of Health Systems Pharmacists Hot Topics in Pharmacy podcast.* Available from: <https://www.ashp.org/professional-development/ashp-podcasts/hot-topics-in-pharmacy-practice/action-in-ambulatory-care-striving-for-diversity-equity-and-inclusion?loginreturnUrl=SSOCheckOnly>. |
|  |
| * Wettergreen S, **Nardolillo JA.** Powerful Placebos and Notorious Nocebos: Implications for Ambulatory Care. *iForumRX podcast. July 2020.* Available from: <https://iforumrx.org/powerful-placebos-and-notorious-nocebos-implications-for-ambulatory-care>. |

**Kaylee Mehlman, PharmD, BCGP, FASCP**

***Published Articles***

* **Mehlman, K**, Ranucci, S. Pharmacist-Delivered Quality in Global Capitation Arrangement. *Sr Care Pharm.* 2023;38:166-7. Available from: [Pharmacist-Delivered Quality in Global Capitation Arrangement: Ingenta Connect](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ingentaconnect.com%2Fcontentone%2Fascp%2Ftscp%2F2023%2F00000038%2F00000005%2Fart00002&data=05%7C01%7CSRanucci%40ripcpc.com%7Ccb0e5272d8b54f5b5a3008db6dd5eefb%7C529ac06642c7499ab6dd3f860727916d%7C0%7C0%7C638224537824809072%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=i99STqWjxivxEuACw7HiH74LGI%2BdBdTIdKUYC%2Fp%2Ff6A%3D&reserved=0).
* **Mehlman, K**, Seibert, C. Post Surgical Thromboprophylaxis – The Need for Evidence Based, Unified Regimens.  *Sr Care Pharm*. 2022;37:250-250(1). Available from:  [Postsurgical Thromboprophylaxis— The Need for Evidence-Base...: Ingenta Connect](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ingentaconnect.com%2Fcontentone%2Fascp%2Ftscp%2F2022%2F00000037%2F00000007%2Fart00003&data=05%7C01%7CSRanucci%40ripcpc.com%7Ccb0e5272d8b54f5b5a3008db6dd5eefb%7C529ac06642c7499ab6dd3f860727916d%7C0%7C0%7C638224537824809072%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=qEKAjabpj%2Boi5nFVaYS6pjXVup8yRXYsC5SAnmaTyxU%3D&reserved=0).
* **Mehlman, K.** The Art of Pharmacy. *Sr Care Pharm.* 2022;37:169-170(2).  Available from:  [The Art of Pharmacy: Ingenta Connect](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ingentaconnect.com%2Fcontentone%2Fascp%2Ftscp%2F2022%2F00000037%2F00000005%2Fart00004&data=05%7C01%7CSRanucci%40ripcpc.com%7Ccb0e5272d8b54f5b5a3008db6dd5eefb%7C529ac06642c7499ab6dd3f860727916d%7C0%7C0%7C638224537824809072%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=0xEr%2BCoGrfe%2BEm%2FQBxLPTBiJ4vlTe81sz4Ki1QMMyxg%3D&reserved=0).
* **Mehlman, K**. Do You Involve Your Pharmacist in Admissions? You should. *McKnights Long-Term Care News.* 10 Feb 2022. Available from: [https://www.mcknights.com/marketplace/marketplace-experts/involve-your-pharmacist-in-admissions/](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.mcknights.com%2Fmarketplace%2Fmarketplace-experts%2Finvolve-your-pharmacist-in-admissions%2F&data=05%7C01%7CSRanucci%40ripcpc.com%7Ccb0e5272d8b54f5b5a3008db6dd5eefb%7C529ac06642c7499ab6dd3f860727916d%7C0%7C0%7C638224537824809072%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2B4CUQ17gSyKmoOjz0k3X88tpaa00HVNDp7AKEePl83o%3D&reserved=0).
* **Mehlman, K**, Cho, V, Myers, T. Electronic Health Record (EHR) Access Importance in Accurately Completing Admission Drug Regimen Reviews. *Sr Care Pharm. 2021;36:350-6.* Available from: [The Importance of Electronic Health Record Access For Accurately Completing Drug Regimen Reviews (researchgate.net)](https://www.researchgate.net/publication/352885039_The_Importance_of_Electronic_Health_Record_Access_For_Accurately_Completing_Drug_Regimen_Reviews).
* Medication Management Strategies. *ASCP COVID-19 (SARS-COV-2) PANDEMIC*. April 2020. Available from:  [https://cdn.ymaws.com/www.ascp.com/resource/resmgr/docs/disaster/covid-19\_\_sars-cov-2\_\_pandem.pdf.](https://cdn.ymaws.com/www.ascp.com/resource/resmgr/docs/disaster/covid-19__sars-cov-2__pandem.pdf.%20)
* Field Guide to Reduce Medication Burden During COVID-19. *ASCP Field Guide to Reduce Medication Burden During COVID-19.* Available from:  [https://cdn.ymaws.com/www.ascp.com/resource/resmgr/docs/disaster/field\_guide\_to\_reduce\_medica.pdf](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcdn.ymaws.com%2Fwww.ascp.com%2Fresource%2Fresmgr%2Fdocs%2Fdisaster%2Ffield_guide_to_reduce_medica.pdf&data=05%7C01%7CSRanucci%40ripcpc.com%7Ccb0e5272d8b54f5b5a3008db6dd5eefb%7C529ac06642c7499ab6dd3f860727916d%7C0%7C0%7C638224537824809072%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=H5qJ1VJGUf2M7z2AVDWvSnGZeKOnQguaCLKoKLSArwU%3D&reserved=0).
* Stough, K, Ferris, D, Margevicius, R, **Adams, K**. Collaboration between a Community Hospital and Extended Care Facility Utilizing an Innovative Transition of Care Process. *ACCP Ambulatory Care Pharmacist’s Survival Guide. 4th Edition.*

**Ron Tutalo, PharmD, BCACP, CDCES, CDOE**

***Published Articles***

* Kimball, BK, **Tutalo, RA**, Minami, T, Eaton, CB. Evaluating an integrated chronic obstructive pulmonary disease management program implemented in a primary care setting. *J Am Coll Clin Pharm*. 2021; 4: 697– 710. Available from: [Evaluating an integrated chronic obstructive pulmonary disease management program implemented in a primary care setting - Kimball - 2021 - JACCP: &nbsp; JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY - Wiley Online Library](https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.1428).
* Wilkinson, J, **Tutalo, R**. Revefenacyin (Yupelri) for the Treatment of Chronic Obstructive Pulmonary Disease *Am Fam Physician 2020 Jan 15;101(2):121-122*. Available from: [Revefenacin (Yupelri) for the Treatment of Chronic Obstructive Pulmonary Disease - PubMed (nih.gov)](https://pubmed.ncbi.nlm.nih.gov/31939643/).

**Stacey Ranucci, BSPharm, BCGP, CDCES, CDOE, FACSP**

***Published Articles***

* Mehlman, K, **Ranucci, S**. Pharmacist-Delivered Quality in Global Capitation Arrangement. *Sr Care Pharm.* 2023;38:166-7. Available from: [Pharmacist-Delivered Quality in Global Capitation Arrangement: Ingenta Connect](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ingentaconnect.com%2Fcontentone%2Fascp%2Ftscp%2F2023%2F00000038%2F00000005%2Fart00002&data=05%7C01%7CSRanucci%40ripcpc.com%7Ccb0e5272d8b54f5b5a3008db6dd5eefb%7C529ac06642c7499ab6dd3f860727916d%7C0%7C0%7C638224537824809072%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=i99STqWjxivxEuACw7HiH74LGI%2BdBdTIdKUYC%2Fp%2Ff6A%3D&reserved=0).
* Reece, R, Chace, P, **Ranucci, S**. Antimicrobial Stewardship in Long-Term Care Facilities. *RI Med J (2013). 2018 June 1; 101(5):42-44.* Available from: [Antimicrobial Stewardship in Long-Term Care Facilities - PubMed (nih.gov)](https://pubmed.ncbi.nlm.nih.gov/29857606/).